Holen Sie sich die Stockscreener-App
21.08
7.56%
-1.66
Vera Therapeutics Inc Aktie (VERA) Neueste Nachrichten
Vera Therapeutics completes enrollment for IgAN drug trial By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $21.44 By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $21.44 - Investing.com India
Vera Therapeutics completes enrollment for IgAN drug trial - Investing.com Australia
Vera Therapeutics completes enrollment in ORIGIN Phase 3 trial for atacicept - TipRanks
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN - GlobeNewswire
Major Milestone: 431 Patients Enrolled in Vera's Groundbreaking IgAN Treatment Trial - Stock Titan
Is Vera Therapeutics Inc (VERA) a threat to investors? - uspostnews.com
Teacher Retirement System of Texas Acquires 3,942 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year LowWhat's Next? - MarketBeat
69,724 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Bought by Raymond James Financial Inc. - Defense World
Vera Therapeutics stock hits 52-week low at $25.97 By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $25.97 - Investing.com India
Vera Therapeutics validates Fair Value bearish call with 42% decline By Investing.com - Investing.com UK
Swiss National Bank Purchases 15,700 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
AlphaQuest LLC Takes Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 7,895 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load? - simplywall.st
Victory Capital Management Inc. Increases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Buy” by Analysts - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of “Buy” from Analysts - The AM Reporter
Vera Therapeutics (VERA) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vera Therapeutics Growth Accelerates: 9 Strategic Hires Secure Equity Package Worth $2.3M - StockTitan
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM
What is HC Wainwright’s Estimate for VERA FY2025 Earnings? - Defense World
Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much? - Seeking Alpha
Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA - Defense World
JPMorgan Chase & Co. Has Lowered Expectations for Vera Therapeutics (NASDAQ:VERA) Stock Price - Defense World
Vera Therapeutics (NASDAQ:VERA) Price Target Cut to $71.00 by Analysts at JPMorgan Chase & Co. - Armenian Reporter
Vera Therapeutics Getting Closer To Key Technical Benchmark - MSN
Rhumbline Advisers Has $2.48 Million Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Q1 EPS Estimates for Vera Therapeutics Boosted by Wedbush - Defense World
(VERA) On The My Stocks Page - news.stocktradersdaily.com
What is Wedbush’s Forecast for VERA FY2029 Earnings? - Defense World
Guggenheim Raises Vera Therapeutics (NASDAQ:VERA) Price Target to $61.00 - Defense World
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $38, Maintains Neutral Rating - Marketscreener.com
Guggenheim raises Vera Therapeutics stock target to $61 - Investing.com India
Can Vera Therapeutics Reveal New Immunology Pipeline Updates at Upcoming TD Cowen Conference? - StockTitan
Optimistic Buy Rating for Vera Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook - TipRanks
Vera Therapeutics targets Q2 for IgAN drug results, FDA filing By Investing.com - Investing.com South Africa
Vera Therapeutics 2024 Loss Widens -February 26, 2025 at 08:53 am EST - Marketscreener.com
Vera Therapeutics targets Q2 for IgAN drug results, FDA filing - Investing.com India
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Total Operating Expenses $167.2M - Marketscreener.com
Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Net Loss $-2.75 a Share, vs. FactSet Est of $-2.90 Loss - Marketscreener.com
Vera Therapeutics, Inc. Reports 2024 Business Highlights and Financial Results; On Track for Phase 3 ORIGIN Trial Results and FDA Submission for Atacicept in IgA Nephropathy - Nasdaq
Can Vera's Breakthrough IgAN Therapy Disrupt the $5B Kidney Disease Market? Phase 3 Results Coming Q2 2025 - StockTitan
Vera Therapeutics’ Atacicept Positioned for Growth Amid Market Overreaction to Otsuka’s Sibeprenlimab - TipRanks
(VERA) Trading Advice - Stock Traders Daily
Vera Therapeutics Inc (VERA) may enjoy gains as insiders got busy in the recent days - Knox Daily
2.65%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):